Targeted Delivery Markets DUALAMS' ultrasonic nebulization technology enables targeted delivery to vocal anatomy and sites accessible to flexible endoscopes, creating a clear value proposition for otolaryngology, anesthesia, and endoscopy-focused procedures. Early customer outreach should target hospitals, ASCs, and specialty clinics performing vocal cord procedures, intubation-related local anesthesia, and targeted drug delivery during endoscopy. Recommend pilot programs with select clinics to demonstrate device performance and patient outcomes; emphasize potential to reduce systemic exposure and improve local efficacy.

Licensing Partnerships With two pending patents and a lean team, DUALAMS could pursue licensing deals or co-development arrangements with larger medical device or pharma companies looking to add targeted delivery capabilities to their portfolio. Potential fits include ultrasound/medical nebulization firms, endoscopy platform manufacturers, and anesthesia suppliers. Prepare a concise value proposition package highlighting IP coverage, potential unit economics, and regulatory pathway requirements.

Strategic Alliances Leverage the Health Wildcatters network and startup ecosystem to connect with customers, distributors, and investors; consider collaboration with academic centers for preclinical and clinical data to accelerate market entry and regulatory readiness. Explore grant funding (SBIR/STTR) to support development and early trials, reducing customer acquisition risk.

Commercialization Path Early-stage commercialization should consider licensing, distributor sales, or service-based integration. Propose a phased plan starting with pilot sites, followed by broader deployment with included training and maintenance. Explore pricing models tied to outcomes, such as reduced local anesthetic use or faster procedure times, to build a compelling ROI case for buyers.

IP Advantage Two pending patents provide a competitive moat around targeted nebulization for vocal cords and endoscopy-accessible sites. Focus on securing freedom-to-operate, pursuing expedited regulatory or licensing routes when possible, and pursuing exclusive licensing arrangements with select partners to maximize value while monitoring competitor activity.